退伍军人健康管理局:以他汀与SLCO1B1基因为例实施药物基因组临床决策支持
本文描述退伍军人健康管理局(VHA)实施临床决策支持工具,提醒处方者注意可操作的药物-基因相互作用。VHA于2019年实施PHASER项目,提供基于面板的抢先药物基因组检测与解读,面板包含SLCO1B1,并利用临床药物基因组学实施联盟他汀指南构建决策支持工具,以降低他汀相关肌肉症状(SAMS)风险并改善疗效。
要点
- VHA通过PHASER项目提供包含SLCO1B1的抢先药物基因组检测与解读。
- 决策支持工具基于临床药物基因组学实施联盟他汀指南构建。
- SLCO1B1表型用于提醒处方者SAMS风险并建议降低剂量或换用他汀。
核心结论
- PHASER项目识别并处理药物-基因相互作用,作为精准医学应用以降低退伍军人不良事件风险。
- 他汀药物基因组学实施利用患者SLCO1B1表型提醒处方者SAMS风险并通过降低剂量或换用他汀降低风险。
- PHASER项目可能有助于减少经历SAMS的退伍军人数量并改善他汀依从性。
研究设计与样本
- 描述VHA实施药物基因组临床决策支持工具的经验,以SLCO1B1基因与他汀为例。
- VHA在2019年实施PHASER项目,提供基于面板的抢先药物基因组检测与解读。
- VHA在2021财年识别约500,000名在VHA开具他汀的新使用者。
主要发现
- PHASER面板包含SLCO1B1,并筛查近40种药物-基因相互作用。
- VHA利用临床药物基因组学实施联盟他汀指南构建临床决策支持工具。
- 决策支持提醒处方者所开具他汀的SAMS风险以及如何通过降低剂量或换用他汀降低风险。
关键数值与推荐
- PHASER面板包含SLCO1B1并筛查近40种药物-基因相互作用。
- 决策支持工具基于临床药物基因组学实施联盟他汀指南构建。
- 提醒内容涉及所开具他汀的SAMS风险以及通过降低剂量或换用他汀降低风险。
临床怎么用
- 处方他汀前可参考SLCO1B1基因型结果,识别SAMS高风险患者。
- 对高风险患者可考虑降低他汀剂量或换用替代他汀以降低SAMS风险。
- 利用临床决策支持工具在处方环节提醒处方者可操作的药物-基因相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the implementation of clinical decision support tools for alerting prescribers of actionable drug-gene interactions in the Veterans Health Administration (VHA). SUMMARY: Drug-gene interactions have been the focus of clinicians for years. Interactions between SCLO1B1 genotype and statin medications are of particular interest as these can inform risk for statin-associated muscle symptoms (SAMS). VHA identified approximately 500,000 new users of statin medications prescribed in VHA in fiscal year 2021, some of whom could benefit from pharmacogenomic testing for the SCLO1B1 gene. In 2019, VHA implemented the Pharmacogenomic Testing for Veterans (PHASER) program to offer panel-based, preemptive pharmacogenomic testing and interpretation. The PHASER panel includes SLCO1B1, and VHA utilized Clinical Pharmacogenomics Implementation Consortium statin guidelines to build its clinical decision support tools. The program's overarching goal is to reduce the risk of adverse drug reactions such as SAMS and improve medication efficacy by alerting practitioners of actionable drug-gene interactions. We describe the development and implementation of decision support for the SLCO1B1 gene as an example of the approach being used for the nearly 40 drug-gene interactions screened for by the panel. CONCLUSION: The VHA PHASER program identifies and addresses drug-gene interactions as an application of precision medicine to reduce veterans' risks for adverse events. The PHASER program's implementation of statin pharmacogenomics utilizes a patient's SCLO1B1 phenotype to alert providers of the risk for SAMS with the statin being prescribed and how to lower that risk through a lower dose or alternative statin selection. The PHASER program may help reduce the number of veterans who experience SAMS and may improve their adherence to statin medications.
引用
- Tomcsanyi KM, Tran KA, Bates J, et al. Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar. Am J Health Syst Pharm. 2023. PMID: 37210707. doi:10.1093/ajhp/zxad111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。